BUZZ-Halozyme Therapeutics hits new record after issuing $1.3 billion in convertible bonds

September 18 - ** Halozyme Therapeutics (HALO.O) shares rose 0.8% to $110.55 on Friday, reaching a record high after the company raised more funds than originally planned

** HALO shares climbed as much as 1.9% to $111.80, surpassing the previous intraday high of $111.15 set on September 3

** The San Diego, California-based drug delivery company announced late Thursday the pricing (link) of an upsized $1.3 billion private placement of convertible bonds (CBs) with a 1.5% coupon, due October 1, 2033

** The $139.84 conversion price is a 27.5% premium to Thursday's closing price of $109.68

** On Thursday, HALO shares closed up 1% after the company (link) announced a $105 million bond offering to repurchase its outstanding 0.25% convertible bonds due 2027 and 1% convertible bonds due 2028; the remaining funds will be used for working capital, capital expenditures, potential acquisitions and other purposes

** The company expects to use about $162.6 million of the raised funds for "capped call transactions" to mitigate potential equity dilution; the cap price of $209.39 represents a 90% premium to the previous trading day's closing price

** HALO has surged 64% so far this year

** According to London Stock Exchange Group (LSEG) data, the average rating from 10 analysts is "Buy"; the median target price is $105, up from $90 on June 18

(To help non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may be inaccurate or may not provide the desired context, Reuters does not guarantee the accuracy of automated translation texts and provides them only as a convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation functions.)